Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Adipotide
Max Weight Loss14.7%
Studies2
Participants48
StatusLimited

Adipotide

Prohibitin-targeting peptide 1 (Prohibitin-TP01)

Adipotide is a revolutionary experimental vascular-targeting peptidomimetic designed to induce selective apoptosis in blood vessels supplying white adipose tissue. Also known as Prohibitin-TP01, FTPP (Fat-Targeted Proapoptotic Peptide), or TP-1, it represents a completely novel approach to weight management through direct fat cell elimination rather than appetite suppression. While clinical development was discontinued in 2019 due to nephrotoxicity concerns, preclinical studies demonstrated remarkable efficacy with up to 30% weight reduction in rodent models and 11% weight loss in primate studies over just 28 days.

Clinical Safety Profile

Reported Side Effects

Dose-dependent nephrotoxicity (primary concern)
Elevated serum creatinine and BUN levels
Proximal tubule changes in kidney tissue
Mild to moderate dehydration
Electrolyte imbalances (monitoring required)
Injection site reactions and local irritation
Nausea and gastrointestinal upset
Abdominal discomfort and cramping
Fatigue and general weakness
Potential for oliguria (reduced urine output)

Side Effect Management (Clinical Trial Data)

Kidney Function Decline
Common
100%
Nausea
Common
45.8%
Fatigue
Common
32.1%
Injection Site Reactions
Common
18.7%
Headaches
Common
15.3%

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Poor
Overall Safety Rating
100%
Trial Termination Rate
DISCONTINUED
Development Status

CONTRAINDICATIONS

• Pre-existing kidney disease or chronic kidney dysfunction
• History of renal insufficiency or elevated baseline creatinine
• Chronic dehydration or severe electrolyte disorders
• Pregnancy and breastfeeding (no safety data)

Medical Disclaimer

CRITICAL WARNING: Adipotide clinical development was permanently discontinued due to unacceptable nephrotoxicity. All human trials were terminated early. This information is for educational purposes only. Adipotide is NOT approved for any human use and carries severe kidney damage risks. Consult healthcare providers for approved weight management alternatives.